Literature DB >> 11882004

Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A(2) based on a 1,3-disubstituted propan-2-one skeleton.

Stephen Connolly1, Colin Bennion, Sarah Botterell, Pamela J Croshaw, Catherine Hallam, Kim Hardy, Paul Hartopp, Clive G Jackson, Sarah J King, Louise Lawrence, Antonio Mete, David Murray, David H Robinson, Gillian M Smith, Linda Stein, Iain Walters, Edward Wells, W John Withnall.   

Abstract

Using knowledge of the substrate specificity of cPLA(2) (phospholipases A(2)), a novel series of inhibitors of this enzyme were designed based upon a three point model of inhibitor binding to the enzyme active site comprising a lipophilic anchor, an electrophilic serine "trap", and an acidic binding moiety. The resulting 1,3-diheteroatom-substituted propan-2-ones were evaluated as inhibitors of cPLA(2) in both aggregated bilayer and soluble substrate assays. Systematic variation of the lipophilic, electrophilic, and acidic groups revealed a well-defined structure-activity relationship against the enzyme. Optimization of each group led to compound 22 (AR-C70484XX), which contains a decyloxy lipophilic side chain, a 1,3-diaryloxypropan-2-one moiety as a unique serine trap, and a benzoic acid as the acidic binding group. AR-C70484XX was found to be among the most potent in vitro inhibitors of cPLA(2) described to date being more than 20-fold more active against the isolated enzyme (IC(50) = 0.03 microM) than the standard cPLA(2) inhibitor, arachidonyl trifluoromethyl ketone (AACOCF(3)), and also greater than 10-fold more active than AACOCF(3) against the cellular production of arachidonic acid by HL60 cells (IC(50) = 2.8 microM).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882004     DOI: 10.1021/jm011050x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

Review 1.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

2.  Binding conformation of 2-oxoamide inhibitors to group IVA cytosolic phospholipase A2 determined by molecular docking combined with molecular dynamics.

Authors:  Varnavas D Mouchlis; Vasiliki Michopoulou; Violetta Constantinou-Kokotou; Thomas Mavromoustakos; Edward A Dennis; George Kokotos
Journal:  J Chem Inf Model       Date:  2012-01-10       Impact factor: 4.956

3.  2-Oxoamide inhibitors of cytosolic group IVA phospholipase A2 with reduced lipophilicity.

Authors:  Georgia Antonopoulou; Victoria Magrioti; Maroula G Kokotou; Aikaterini Nikolaou; Efrosini Barbayianni; Varnavas D Mouchlis; Edward A Dennis; George Kokotos
Journal:  Bioorg Med Chem       Date:  2016-07-27       Impact factor: 3.641

4.  Location of inhibitors bound to group IVA phospholipase A2 determined by molecular dynamics and deuterium exchange mass spectrometry.

Authors:  John E Burke; Arneh Babakhani; Alemayehu A Gorfe; George Kokotos; Sheng Li; Virgil L Woods; J Andrew McCammon; Edward A Dennis
Journal:  J Am Chem Soc       Date:  2009-06-17       Impact factor: 15.419

5.  Expression of phospholipases A2 in primary human lung macrophages: role of cytosolic phospholipase A2-alpha in arachidonic acid release and platelet activating factor synthesis.

Authors:  Giorgio Giannattasio; Ying Lai; Francescopaolo Granata; Carine M Mounier; Laxman Nallan; Rob Oslund; Christina C Leslie; Gianni Marone; Gérard Lambeau; Michael H Gelb; Massimo Triggiani
Journal:  Biochim Biophys Acta       Date:  2008-12-16

6.  Lung mast cells are a source of secreted phospholipases A2.

Authors:  Massimo Triggiani; Giorgio Giannattasio; Cecilia Calabrese; Stefania Loffredo; Francescopaolo Granata; Alfonso Fiorello; Mario Santini; Michael H Gelb; Gianni Marone
Journal:  J Allergy Clin Immunol       Date:  2009-07-09       Impact factor: 10.793

7.  Pharmacophore-based discovery of a novel cytosolic phospholipase A(2)α inhibitor.

Authors:  Stefan M Noha; Bianca Jazzar; Susanne Kuehnl; Judith M Rollinger; Hermann Stuppner; Anja M Schaible; Oliver Werz; Gerhard Wolber; Daniela Schuster
Journal:  Bioorg Med Chem Lett       Date:  2011-11-30       Impact factor: 2.823

8.  Group X secreted phospholipase A(2) induces lipid droplet formation and prolongs breast cancer cell survival.

Authors:  Anja Pucer; Vesna Brglez; Christine Payré; Jože Pungerčar; Gérard Lambeau; Toni Petan
Journal:  Mol Cancer       Date:  2013-09-27       Impact factor: 27.401

Review 9.  pCRP-mCRP Dissociation Mechanisms as Potential Targets for the Development of Small-Molecule Anti-Inflammatory Chemotherapeutics.

Authors:  Vittorio Caprio; Lina Badimon; Mario Di Napoli; Wen-Hui Fang; Glenn R Ferris; Baoqiang Guo; Rocco S Iemma; Donghui Liu; Yasmin Zeinolabediny; Mark Slevin
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

10.  A New Generation of Arachidonic Acid Analogues as Potential Neurological Agent Targeting Cytosolic Phospholipase A2.

Authors:  Cheng Yang Ng; Srinivasaraghavan Kannan; Yong Jun Chen; Francis Chee Kuan Tan; Wee Yong Ong; Mei Lin Go; Chandra S Verma; Chian-Ming Low; Yulin Lam
Journal:  Sci Rep       Date:  2017-10-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.